Teva Pharmaceutical Industries Investing Activities - Other 2010-2025 | TEVA
Teva Pharmaceutical Industries annual/quarterly investing activities - other history and growth rate from 2010 to 2025. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- Teva Pharmaceutical Industries investing activities - other for the quarter ending March 31, 2025 was $322M, a 9.15% increase year-over-year.
- Teva Pharmaceutical Industries investing activities - other for the twelve months ending March 31, 2025 was $3.178B, a 9.36% decline year-over-year.
- Teva Pharmaceutical Industries annual investing activities - other for 2024 was $1.293B, a 12.16% decline from 2023.
- Teva Pharmaceutical Industries annual investing activities - other for 2023 was $1.472B, a 29.12% increase from 2022.
- Teva Pharmaceutical Industries annual investing activities - other for 2022 was $1.14B, a 30.87% decline from 2021.
Teva Pharmaceutical Industries Annual Investing Activities - Other
(Millions of US $) |
| 2024 |
$1,293 |
| 2023 |
$1,472 |
| 2022 |
$1,140 |
| 2021 |
$1,649 |
| 2020 |
$1,417 |
| 2019 |
$1,545 |
| 2018 |
$1,746 |
| 2017 |
$1,000 |
| 2016 |
$-212 |
| 2015 |
$-5 |
| 2014 |
$-30 |
| 2013 |
$-104 |
| 2012 |
$-93 |
| 2011 |
$-49 |
| 2010 |
$-58 |
| 2009 |
$-35 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.026B |
$16.544B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
